Clinico-demographic characteristics and outcomes of radiation-induced sarcomas (RIS): a CanSaRCC study.

"Declarations Ethics approval and consent to participate: Patients provided written consent allowing their personal information to be stored and extracted from the CanSaRCC database for studying purposes (master CanSaRCC protocol REB 10-0804). The present project was also approved by our local institutional review board (REB 20-5520).Consent for publication: Not applicable.Author contributions:Mauricio Fernando Ribeiro: Conceptualization; Data curation; Formal analysis; Methodology; Writing – original draft; Writing – review & editing.Hagit Peretz Soroka: Conceptualization; Data curation; Formal analysis; Methodology; Project administration; Writing – review & editing.Zainab Bhura: Data curation; Writing – review & editing.Ian Hirsch: Writing – review & editing.Jay Wunder: Writing – review & editing.Peter Ferguson: Writing – review & editing.Kim Tsoi: Writing – review & editing.Savtaj Brar: Writing – review & editing.Rebecca Gladdy: Writing – review & editing.Carol Swallow: Writing – review & editing.Peter Chung: Writing – review & editing.Charles Catton: Writing – review & editing.Philip Wong: Writing – review & editing.Geoffrey Watson: Writing – review & editing.Albiruni Ryan Abdul Razak: Writing – review & editing.Abha A. Gupta: Conceptualization; Methodology; Supervision; Writing – review & editing.David Shultz: Conceptualization; Methodology; Supervision; Writing – review & editing.Funding: The authors received no financial support for the research, authorship, and/or publication of this article.Competing interests: M.F.R. – honoraria: Bristol Myers Squibb. G.W. – honoraria: Pfizer, Gilead Sciences; consulting/advisory role: Novartis; travel grants: Abbvie. A.A.R. – consulting/advisory role: Adaptimmune, Bayer, GlaxoSmithKline, Inhibrx, Medison; expert testimony: Medison; research funding: 23andMe, Abbvie, Adaptimmune, Amgen, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Deciphera, Frontier Therapeutics, GlaxoSmithKline, Iterion Therapeutics, Karyopharm Therapeutics, MedImmune, Merck, Neoleukin Therapeutics, Pfizer, Rain Therapeutics, Roche/Genentech, Symphogen. H.P.S., Z.B., I.H., J.W., P.F., K.T., S.B., R.G., C.S., P.C., C.C., P.W., A.A.G., D.S. – no competing interests to disclose.Availability of data and materials: Access to specific data and analyses can be requested through cansarcc@uhn.ca. Competing interests: M.F.R. – honoraria: Bristol Myers Squibb. G.W. – honoraria: Pfizer, Gilead Sciences; consulting/advisory role: Novartis; travel grants: Abbvie. A.A.R. – consulting/advisory role: Adaptimmune, Bayer, GlaxoSmithKline, Inhibrx, Medison; expert testimony: Medison; research funding: 23andMe, Abbvie, Adaptimmune, Amgen, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Deciphera, Frontier Therapeutics, GlaxoSmithKline, Iterion Therapeutics, Karyopharm Therapeutics, MedImmune, Merck, Neoleukin Therapeutics, Pfizer, Rain Therapeutics, Roche/Genentech, Symphogen. H.P.S., Z.B., I.H., J.W., P.F., K.T., S.B., R.G., C.S., P.C., C.C., P.W., A.A.G., D.S. – no competing interests to disclose."

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."